165P Immune characterization of the de novo oligometastatic breast cancer

Abstract

Background: Detection of the human epidermal growth factor receptor 2 gene (HER2, also known as erbB2) expression is important to decide a treatment strategy for breast cancer patients. 20 to 30% of breast cancer patients overexpress HER2. The reference methods for determining HER2 protein expression are Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Although both methods are reliable, they are complex, time-consuming and expensive.